Botulium Toxin Type A In Non Infectious Chronic Rhinosinusitis

Benha University30 enrolled

Overview

The present work aims to assess the effectiveness and safety of topical application of BTX - A compared with its intra turbinate injection in controlling the symptoms in non infectious chronic rhinosinusitis patients

A prospective comparative study will be carried out on 30 participant of both sex at Otorhinolaryngology Department, Benha University Hospital, it will include patients suffering from non infectious chronic rhinosinustitis symptoms in the form of nasal blockage, rhinorrhea, itching and/or sneezing. The patients will be divided randomly into two groups: * Group A (topical group) : 15 patients * Group B (injected group) : 15 patients All patients will be subjected to: 1. Full clinical evaluation: A) Full history taking B) Clinical examination by * anterior rhinoscopy to evaluate the nasal cavity to exclude purulent discharge , nasal polyps or anterior septal deviation. * nasal endoscopy to exclude nasal infection signs ,nasal polyps ,the posterior septal deviation or adenoid . C) Investigations:CT nose and paranasal sinuses coronal cuts to exclude fungal sinusitis, nasal polyps or other structural abnormalities e.g; posterior septal deviation, conchae bullosa or any other nasal pathology . 2. Intervention : * BTX -A available in the Egyptian market in the form of powder vial (Allergan) containing 100 Units, will be dissolved in 10 cc saline to obtain clear colorless solution in which each 1cc contain 10 Units. * In group A (topical group) ,topical application in the form of merocel soaked with 20 units of BTX\_A (2ml) will be placed at each side of the nasal cavity for 30 minutes. * In group B (injected group), 20 units of BTX\_A (2ml) will be injected submucosally in each inferior turbinate using insulin syringe needle after local anesthesia using 10% xylocaine spray . 3. Follow Up Follow up visits will be at 1,2,4,6,8 weeks, patients will be assessed and questionnaired about severity of the symptoms and possible adverse effects including epistaxis and nasal dryness .

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Chronic Rhinosinusitis (Diagnosis)

Interventions

BTX A TopicalDRUG

In group A (topical group) ,topical application in the form of merocel soaked with 20 units of BTX\_A (2ml) will be placed at each side of the nasal cavity for 30 minutes.

BTX A InjectionDRUG

In group B (injected group), 20 units of BTX\_A(2ml) will be injected submucosally in each inferior turbinate using insulin syringe needle after local anesthesia using 10% xylocaine spray .

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients with persistent symptoms of chronic non infectious rhinosinusitis not responding to previous lines of treatment including antihistaminics ,nasal decongestant, and or nasal steroid spray will be included in this study. Exclusion Criteria: * Patients with major structural deformities(septal deviation , adenoid hypertrophy, nasal valve pathology or nasal polyps). * Having systemic illness such as DM, HTN, Malignancy or Tuberculosis. * History of nasal surgery such as turbinate reduction surgery orseptoplasty. * Acute rhinosinusitis findings; e.g purulent or mucopurulent nasal discharge * Radiological finding of nasal tumors or fungal sinusitis. * Any accompanying disease such as glaucoma or prostate hypertrophy or myasthenia that might be aggravated by anticholinergic therapy . * use of systemic or local corticosteroid less than 1 month prior the study. * Pregnancy or lactation. * History of allergy to botox or local anesthetic agents.

Locations (1)

Benha University Hospital, Faculty of Medicine

Banhā, Qalyubia Governorate, Egypt

Outcomes

Primary Outcomes

the rhinitis symptom severity

the rhinitis symptom severity questionnaire, this is questionnaire consists of 4 items (nasal obstruction, rhinorrhea , sneezing and or nasal itching) . each symptom given score from 0 to 3 ( 0 = none, 1 = mild, 2 = moderate and 3 = severe)

Time frame: 2 months

Secondary Outcomes

possible adverse effects

epistaxis and nasal dryness (yes/no)

Time frame: 2 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.